Research Projects

Principle InvestigatorDepartmentStudy Title
Vesna SossiPacific Parkinson's Research CentreInvestigation of Treatment Related Compulsive Behaviours and Impulse Control Disorders in Parkinson's Disease
Vesna SossiPacific Parkinson's Research CentreThe Study of Proton Therapy Dose Distribution
Vesna SossiPacific Parkinson's Research CentreImaging Inflammation with PBR28 in healthy controls
A. Jon StoesslPacific Parkinson's Research CentreImaging Tau Accumulation with PBB3 in Healthy Controls
A. Jon StoesslPacific Parkinson's Research CentreTau and Neuroinflammation Imaging in Parkinson's Disease and Related Disorders
A. Jon StoesslPacific Parkinson's Research CentreThe Evolution of Parkinson's Disease
A. Jon StoesslPacific Parkinson's Research CentreThe Relationship Between Serotonergic Innervation and levadopa-Derived Dopamine Release in Parkinson's Disease: An In Vivo PET Study
A. Jon StoesslPacific Parkinson's Research CentreExercise and Parkinson's Disease: The basis for motor and cognitive benefits
A. Jon StoesslPacific Parkinson's Research CentreStudies of Dopamine Pathways by PET
A. Jon StoesslPacific Parkinson's Research CentreStudies of Patients with a high Genetic Risk of Developing Parkinson's Disease; Studies on the Natural History of Sporadic and Inherited Parkinson's Disease
A. Jon StoesslPacific Parkinson's Research CentreHuman PET Studies of the Monamine Vesicular Transporter and human PET studies of the D1 receptor/MVT (Sch/TBZ)
A. Jon StoesslPacific Parkinson's Research CentreC-11 Raclopride for human PET studies D2 Receptors (Raclopride)
A. Jon StoesslPacific Parkinson's Research CentrePET Studies of Cerebral Glucose Metabolism in Neurodegenerative and Related Disorders
Robert CarruthersMultiple Sclerosis Clinic, NeurologyPilot Study of PET Imaging; Correlation with Advanced MRI and Optical Coherence Tomography (OCT) in MS
Lakshmi YathamMood and Anxiety Disorders, PsychiatryPET Studies of Dopamine Turnover and Release in Bipolar Disorder - Montreal Imaging Stress Task PET Study
Haakon NygaardClinic for Alzheime Disease and Related Disorders, NeurologyA Medium Chain Triglyceride INTervention for Alzheimer's Disease (A MINT for AD) Phase Study
Haakon NygaardClinic for Alzheime Disease and Related Disorders, NeurologyA Phase 2a Multi-Centre Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyCharacterization of Dementia Due to Mixed Alzheimer and Subcortical Vascular Pathology
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyA Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Centre Study of 2 Potential Disease Modifying Therapies in Individual at Risk for and with Dominantlyy Inherited Alzheimer's Disease
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyAlzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyAlzheimer's Disease Neuroimaging Initiative 2 (ADC-039)
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyAnti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study (A4 Study)
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyMedical Imaging Trial NEtwork of Canada (MINTEC) Protocol C6: Amyloid and glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients with Significant White Matter Disease
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyA 24-month, multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyNovel Retinal Biomarkerss for Alzheimer's disease(" Retinal Imaging for Dementia")
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyA Phase 3 Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumb (BIIB037) in Subjects with Early Alzheimer's Disease
G. Y. Robin HsiungClinic for Alzheime Disease and Related Disorders, NeurologyA Phase III, Multicente, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab In Patients With Prodromal To Mild Alzheimer's Disease
Doris DoudetPacific Parkinson's Research CentreControl Study for the Validation of C-11 yohimbine as a Selective Tracer for the Alpha 2 Adrenergic Receptors
Catharine A. WinstanleyPsychologyDopamine release in Response to Gambling: a [11C]raclopride PET pilot study
Alexandre Henri-BhargavaClinical-Island Medical Program, NeurologyCREAD: A Phase III, Multicente, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab In Patients With Prodromal To Mild Alzheimer's Disease
Alexandre Henri-BhargavaClinical-Island Medical Program, NeurologyA 24-month, multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A. Jon StoesslPacific Parkinson's Research CentreTreating Depression in Parkinson's Disease with Transcarnial Direct Current Stimulation